Researchers disrupt molecule that causes excess mucus in lungs, may prompt new treatments for pulmonary disease Excess mucus in the lungs can be fatal.
(2)
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients
REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time. Webcast registration and participation link appears below
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ( Jaguar or the Company ) announced today that the Company has entered a binding agreement of terms (the Term Sheet ) for $6.0 million for the sale of partial rights to a possible tropical disease priority review voucher ( TDPRV ). Per the terms of the Term Sheet, Streeterville Capital, LLC (the Investor ), has a right to 18% of the sale of a TDPRV that Jaguar s wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo) plans to pursue as incentive for the development of Napo s lechlemer drug product candidate for the indication of the symptomatic relief